A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.
Phase 4
Terminated
- Conditions
- AnemiaChronic Renal Insufficiency
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 8
- Registration Number
- NCT00495365
RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia
Phase 4
Terminated
- Conditions
- ChemotherapyAnemiaCancer
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 25
- Registration Number
- NCT00495378
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Phase 3
Terminated
- Conditions
- AnemiaNeoplasms
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 98
- Registration Number
- NCT00350090
A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)
Phase 4
Terminated
- Conditions
- AnemiaKidney Diseases
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 13
- Registration Number
- NCT00338468
A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)
Phase 2
Completed
- Conditions
- Hepatitis CAnemia
- First Posted Date
- 2006-05-22
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 105
- Registration Number
- NCT00328549
An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)
Phase 4
Completed
- Conditions
- AnemiaHIV Infections
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 292
- Registration Number
- NCT00317902
NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus Coinfection
Phase 2
Completed
- Conditions
- Hepatitis CHIVAnemia
- First Posted Date
- 2006-04-18
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 91
- Registration Number
- NCT00315432
Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia
Phase 4
Completed
- Conditions
- AnemiaChemotherapy
- First Posted Date
- 2006-04-18
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 358
- Registration Number
- NCT00315484
A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)
Phase 2
Completed
- Conditions
- AnemiaChronic Renal Insufficiency
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 519
- Registration Number
- NCT00307814
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy
Phase 3
Completed
- Conditions
- AnemiaHodgkin DiseaseLeukemiaLymphoma, Non-hodgkin
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 224
- Registration Number
- NCT00261677
© Copyright 2025. All Rights Reserved by MedPath